Cellectar Biosciences, Inc.

Cellectar Biosciences, Inc. is a biotechnology firm focused on developing innovative cancer therapies through its unique Phospholipid Drug Conjugate™ platform, enhancing targeted drug delivery and treatment efficacy. Founded in 1996 and headquartered in Florham Park, US, Cellectar Biosciences, Inc. specializes in cancer drug development.

The company has not pivoted its business strategy since its inception. Its CEO is Jim Caruso. In April 2011, the company raised USD 5. 14 mn through a PIPE funding round led by Venture Investors, marking the total amount raised to USD 5.

14 mn. Cellectar Biosciences, Inc. specializes in the development of proprietary drugs aimed at treating cancer, leveraging its Phospholipid Drug Conjugate™ (PDC) platform. The company's lead product, iopofosine I 131, is designed for targeted delivery of iodine-131 (a radioisotope) to cancer cells, enhancing treatment efficacy while minimizing off-target effects.

This innovative approach allows for improved outcomes in patients with various cancers, including those with Waldenstrom’s macroglobulinemia, where pivotal clinical studies are currently underway. Cellectar's product pipeline also includes proprietary preclinical PDC chemotherapeutic programs and partnered assets, all aimed at addressing the metabolic dependencies of tumor cells across multiple cancer types. Geographically, Cellectar targets markets within the United States and potentially Europe, focusing on oncology specialists, healthcare providers, and research institutions as key end users of their therapeutic products. Cellectar Biosciences generates revenue through partnerships and clinical trial collaborations with pharmaceutical companies and research entities.

The transactions typically involve licensing agreements for the use of their PDC technology in developing new cancer treatments or co-development arrangements for existing products. The company’s flagship product, iopofosine I 131, is positioned in the market to attract oncology-focused healthcare providers and institutions seeking innovative treatment options for their patients. Revenue is structured through milestone payments and royalties, reflecting the progress of clinical trials and successful commercialization efforts. Through these collaborations, Cellectar aims to establish a sustainable revenue model that supports ongoing research and development within its extensive product pipeline.

Cellectar Biosciences, Inc. plans to leverage the USD 5. 14 mn raised in April 2011 to support the advancement of its clinical programs and the development of new PDC-based products. The company is focused on expanding its product offerings and pursuing additional partnerships to enhance its market presence in the oncology field.

Specific geographic expansion plans include targeting markets in Europe and the United States, with a particular emphasis on reaching out to oncology specialists and research institutions by the end of 2024.